Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01808560 · ClinicalTrials.gov registry record · NA
Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery
A NA study, sponsored by TearScience.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT01808560 is a NA study that has completed, run by TearScience. The registered enrollment target is 34 participants.
The verdict
NCT01808560, a NA study, has completed, sponsored by TearScience.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this pilot feasibility study is to assess whether treating meibomian gland dysfunction (MGD) prior to cataract surgery helps promote meibomian gland function, visual quality and ocular comfort after cataract surgery.
Interventions
- DEVICE LipiFlow Pre-Treatment
- DEVICE LipiFlow Post-treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01808560
The ClinicalTrials.gov registry entry for NCT01808560 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TearScience, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LipiFlow Pre-Treatment is the first listed.
NCT01808560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01808560 about?
NCT01808560 is a clinical study titled "Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery". The purpose of this pilot feasibility study is to assess whether treating meibomian gland dysfunction (MGD) prior to cataract surgery helps promote meibomian gland function, visual quality and ocular comfort after cataract surgery.
What is the current status of trial NCT01808560?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2013-03. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01808560?
The interventions under investigation include: LipiFlow Pre-Treatment (DEVICE), LipiFlow Post-treatment (DEVICE).
Who is sponsoring clinical trial NCT01808560?
This trial is sponsored by TearScience, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.